IL1B and myocardial infarction: Abatacept was found to have 20% greater CV risk reduction than anti-TNF agents; tocilizumab had the same effect on CV risk as MTX monotherapy; anakinra showed improved vascular and left ventricular function in a small placebo-controlled study; sarilumab and rituximab had a neutral effect on CV events; and canakinumab, an IL-1 inhibitor of 150 mg administered every 3 months, was associated with a significantly lower rate of myocardial infarction than the placebo [76,129,130,131,132,133,134].